As the first buildings at Port Covington begin to rise, the project’s developers have a vision for the mini-city sprouting on a South Baltimore peninsula as the nation’s next big biotech hub.
The waterfront neighborhood of apartments, offices, stores and parks now under construction could rival life sciences cores such as Cambridge, Massachusetts, and Mission Bay in San Francisco, members of the development team say.
BioHealth Innovation, Inc. (BHI), is a Montgomery County innovation intermediary that translates market-relevant research into commercial success by bringing together management, funding, and markets. BHI is seeking two experienced life science professionals with product development and investment experience to join the BHI team to serve as a part-time Entrepreneurs-in-Residence (EIR) at the National Institutes of Health (NIH).
These positions will report to and work closely with our lead at the NIH Small business Education and Entrepreneurial Development (SEED) Office to support academic and small business innovators in their efforts to validate the potential health impacts of promising scientific discoveries and advance them into healthcare products that improve patient care and enhance health.
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. This week we welcome Sue Carr, RPh, President and Founder, CarrTech, LLC.
Sue Carr RPh is President and Founder of CarrTech LLC, a medical device company. CarrTech has developed, patented, and prototyped an all-in-one package one needle filter device to increase safety and compliance while reducing time and waste. Sue has over 30 years of experience in the pharmaceutical industry in retail management and clinical hospital pharmacy, specializing in ICU, ER, Oncology, and NICU.
GrowthCap is pleased to announce The Top 25 Healthcare Investors of 2021. In our inaugural year for these awards, we wanted to bring forth and recognize not only the most experienced and talented investors in healthcare but also those that help advance innovation across the sector. Over 750 investors were considered. Whether in healthcare software, healthcare services, medical technologies, biotechnology, the connected patient experience, or other areas, the accomplished individuals who were ultimately selected have demonstrated a deep commitment to healthcare and as a result have succeeded both from a business standpoint as well as in having significant societal impact.
Image: https://growthcapadvisory.com
As biopharma companies continue to cope with the COVID-19 pandemic and position themselves for recovery, digital and analytics can be a powerful tool in manufacturing and operations. It can drive the next wave of business optimization by transforming operational performance, shortening time to market, improving quality and yield, reducing supply chain volatility, and accelerating technology transfers.
There is no denying that the venture capital industry is red hot right now. When you open up websites like Forbes, Techcrunch, and Business Insider, it is almost impossible to miss all of the news about the biggest deals in Silicon Valley being made by these firms.
Anew partnership led by University of Maryland researchers has entered a cooperative agreement with the U.S. Army Research Laboratory (ARL) that could provide up to $68 million to drive advances in artificial intelligence and autonomy.
An interdisciplinary research team from UMD and the University of Maryland, Baltimore County (UMBC) aims to create a new generation of technologies and devices—from wearables to unmanned aircraft—able to intelligently work alone or in teams with other devices, as well as safely and effectively collaborate with their human operators in different environments.
Saw a familiar face on ABC News 7 tonight! Congrats to the American Gene Technologies International Inc. team on the first patient dosing in the #HIVCure Ph 1 trial. ??☝?
Five finalists have been named in the prestigious annual “Make Your Medical Device Pitch for Kids!” competition presented by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI). Representing innovations in electrophysiology devices that treat congenital heart disease (CHD) and arrhythmias in pediatric patients, these five finalists now have access to a pediatric accelerator program led by MedTech Innovator and will compete for a share of $150,000 in grant funding from the U.S. Food and Drug Administration (FDA) in the final virtual pitch event in September 2021. The pediatric pitch event is part of the 9th Annual Symposium on Pediatric Device Innovation, co-located with the MedTech Conference, powered by AdvaMed.
HILDEN, Germany & GERMANTOWN, Md.–(BUSINESS WIRE)– QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global collaboration with Mirati Therapeutics Inc. (NASDAQ:MRTX) to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib, Mirati’s investigational, highly selective and potent oral small molecule inhibitor of KRASG12C.
